Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix for approximately $935 million in cash, translating to $8.55 per share. This acquisition aims to enhance Jazz's portfolio with Chimerix's brain cancer therapy, which has recently gained alignment with the FDA for a path to accelerated approval. Following the announcement, Chimerix's stock surged by 69%, reflecting investor optimism regarding the deal. Jazz is expected to generate total revenue of between $4.15 billion and $4.40 billion in 2025, bolstered by this acquisition and a promising pipeline that includes other therapies.
First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal https://t.co/AcQw1cSBG8
Truist $JAZZ Dordaviprone Could Be Accretive Near Term. Promising Pipeline An Upside. Raising PT To $230 - This AM, JAZZ announced decision to acquire Chimerix $CMRX, NR) in an all cash transaction for $935M or $8.55 per share
#ZYDUSLIFE Zydus Lifescience jumps 3.15% on receiving USFDA final approval to manufacture Dasatinib Tablets (20 mg - 140 mg), a key drug for Ph+ CML & Ph+ ALL treatment. 💊 🔹 Manufactured at Zydus SEZ, Ahmedabad 🔹 US market size: $1.8B (IQVIA, Jan 2025) #StockMarket #Pharma…
